Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

10 articles from the last 90 days matching "surgery"

NewsRSSToday

Words of wisdom for living well with Parkinson’s disease

A person with Parkinson's disease shares their experience living well with the condition after receiving deep brain stimulation surgery. They started a weekly walking group three years ago to stay active and connected with others. The article focuses on practical tips and lifestyle strategies for managing Parkinson's disease day-to-day.

WHY IT MATTERSThis firsthand account demonstrates how deep brain stimulation combined with regular physical activity and social engagement can help people with Parkinson's disease maintain quality of life and independence.
Good to knowParkinson's diseaseRead →
NewsRSS2 days ago

Ironing out low ferritin levels after surgery for SMAS

A patient with Superior Mesenteric Artery Syndrome (SMAS) who had surgery is experiencing low iron levels (low ferritin), which is causing severe fatigue, brain fog, restless legs at night, and poor sleep. The article discusses how iron deficiency after SMAS surgery can make recovery harder and affect quality of life.

WHY IT MATTERSPatients recovering from SMAS surgery need to know that low ferritin levels are a treatable complication that directly causes the exhaustion and cognitive problems they may be experiencing post-operatively.
💬 Ask your doctorSuperior Mesenteric Artery SyndromeRead →
Clinical trialCLINICALTRIALS3 days ago

Trial Now Recruiting: Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. (NCT06563999)

Researchers are looking for patients with advanced lung cancer (stage III) that cannot be removed with surgery and has unusual genetic mutations. The study will test whether giving patients targeted drugs based on their specific genetic mutation, followed by surgery, works better than standard treatment. About 120 patients will participate in this research.

WHY IT MATTERSIf you have unresectable stage III NSCLC with a rare mutation, this trial offers access to personalized treatment tailored to your specific genetic profile before surgery—an approach not yet widely available outside research settings.
You can act on thisNon-small-cell lung cancer (NSCLC), stage III, unresectableRead →
Clinical trialCLINICALTRIALSApr 6

Trial Now Recruiting: A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection (NCT07128199)

Researchers are testing a new drug called zipalertinib to see if it helps people with early-stage lung cancer that has specific genetic mutations. Patients who had surgery to remove their tumors will receive either the new drug or a placebo (fake medicine) along with standard chemotherapy. The study wants to find out if zipalertinib can prevent the cancer from coming back better than chemotherapy alone.

WHY IT MATTERSIf you have early-stage NSCLC with uncommon EGFR mutations (like exon 20 insertions) and recently had surgery, this trial offers access to a targeted therapy specifically designed for your mutation type before it becomes widely available.
You can act on thisnon-small cell lung cancerNSCLC with uncommon EGFR mutationsearly-stage lung cancerRead →
Clinical trialUNITERAREApr 5

New Recruiting Trial: Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma

Researchers are looking for patients with a rare cancer called adrenocortical carcinoma that has come back after surgery. This study will test whether giving radiation therapy before surgery helps remove the cancer more effectively. The trial is just starting and will enroll patients beginning in April 2026.

WHY IT MATTERSThis is the first Phase 1 trial testing preoperative radiation for recurrent adrenocortical carcinoma, offering eligible patients access to a potentially new treatment approach before it becomes widely available.
👁 Watch this spaceadrenocortical carcinomaRead →
Clinical trialUNITERAREApr 3

New Recruiting Trial: Anthocyanin-Rich Table Grape Powder for Prophylaxis of Post-Operative Atrial Fibrillation

Researchers at the University of Michigan are testing whether a powder made from grapes rich in anthocyanins (natural plant compounds) can help prevent atrial fibrillation—a heart rhythm problem—after heart surgery. This early-stage trial is now accepting patients. The study will test if this natural supplement is safe and if it works better than a placebo (fake treatment).

WHY IT MATTERSThis trial offers patients undergoing heart surgery a potential natural option to reduce their risk of developing irregular heartbeats after the operation, which affects up to 50% of post-operative cardiac patients.
💬 Ask your doctorAtrial FibrillationRead →
Clinical trialUNITERAREApr 3

New Recruiting Trial: Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

This is a clinical trial testing a blood clotting medicine called Nuwiq in women and girls with hemophilia A who need surgery. Hemophilia A is a rare bleeding disorder where the body doesn't make enough of a protein that helps blood clot. The trial will study how well Nuwiq works and what dose is best for these patients during surgical procedures.

WHY IT MATTERSThis trial is specifically designed for women and girls with hemophilia A undergoing surgery — a population that often receives less research attention than males with the same condition.
You can act on thisHemophilia ARead →
Clinical trialCLINICALTRIALSApr 1

Trial Now Recruiting: Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors (NCT07374692)

Researchers are testing a new technology called SmartMatch that helps doctors find the best cancer medicines for patients with rare brain and spinal cord tumors. The technology works by taking a small piece of tumor removed during surgery and testing it against different drugs to see which ones work best. The study wants to see if SmartMatch can complete this analysis and give doctors a report within 3 weeks of surgery. This trial is looking for 80 patients with various types of brain tumors.

WHY IT MATTERSThis trial offers patients with recurrent or advanced brain tumors access to personalized drug testing that could identify the most effective treatment for their specific tumor type within weeks of surgery.
You can act on thisRecurrent Central Nervous System TumorsBrain CancerGliomasRead →
ResearchPUBMEDMar 26

[A rare cause of otitis externa : Manifestation of myeloid sarcoma in the petrous bone].

A 45-year-old man had ear canal swelling and an ear infection that wouldn't go away with normal treatment. Doctors performed surgery but didn't find the cause at first. After more testing, they discovered the real problem: cancer cells from a blood disease called acute myeloid leukemia (AML) had come back and were growing in the bone behind his ear.

WHY IT MATTERSThis case shows that persistent ear infections that don't respond to standard treatment could be a sign of leukemia relapse, meaning AML patients with unusual ear symptoms need urgent investigation beyond typical infection treatment.
💬 Ask your doctorAcute Myeloid Leukemia (AML)Myeloid SarcomaOtitis ExternaRead →
Clinical trialCLINICALTRIALSMar 26

Trial Now Recruiting: Functional and Morphological Characterization of Multiple Osteochondromas Disorder (NCT06703736)

Researchers are looking for 60 people with hereditary multiple osteochondromas (a condition where benign bone tumors grow in multiple places on the body) to join a study. The study will measure how these tumors affect body shape, movement, and function in both children and adults. The goal is to better understand the disease and help doctors decide when surgery is needed.

WHY IT MATTERSThis trial is actively recruiting patients with hereditary multiple osteochondromas and could help establish better guidelines for when surgical treatment should happen, potentially improving outcomes for both pediatric and adult patients.
You can act on thisHereditary Multiple OsteochondromasMultiple Osteochondromas DisorderRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases